Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: opat s. Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5. Lancet Oncol. 2020. PMID: 32888452 Clinical Trial.
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study.
Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM. Odutola MK, et al. Among authors: opat ss. Front Nutr. 2023 Jan 4;9:1048301. doi: 10.3389/fnut.2022.1048301. eCollection 2022. Front Nutr. 2023. PMID: 36687712 Free PMC article.
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.
Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Tam CS, et al. Among authors: opat s. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990. Blood Adv. 2023. PMID: 36753605 Free PMC article. No abstract available.
Correction: Zanubrutinib: past, present, and future.
Tam CS, Muñoz JL, Seymour JF, Opat S. Tam CS, et al. Among authors: opat s. Blood Cancer J. 2023 Oct 2;13(1):154. doi: 10.1038/s41408-023-00926-3. Blood Cancer J. 2023. PMID: 37783709 Free PMC article. No abstract available.
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk.
Odutola MK, van Leeuwen MT, Bruinsma F, Turner J, Hertzberg M, Seymour JF, Prince HM, Trotman J, Verner E, Roncolato F, Opat S, Lindeman R, Tiley C, Milliken ST, Underhill CR, Benke G, Giles GG, Vajdic CM. Odutola MK, et al. Among authors: opat s. Cancer Epidemiol Biomarkers Prev. 2024 Jan 9;33(1):106-116. doi: 10.1158/1055-9965.EPI-23-0578. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 37831120 Free PMC article.
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study.
Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM. Odutola MK, et al. Among authors: opat s. Occup Environ Med. 2023 Oct;80(10):599-602. doi: 10.1136/oemed-2023-108949. Epub 2023 Sep 18. Occup Environ Med. 2023. PMID: 37722828 Free PMC article.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: opat s. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. Awan FT, et al. Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8. Br J Haematol. 2014. PMID: 25130401 Free article. Clinical Trial.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Burger JA, et al. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. N Engl J Med. 2015. PMID: 26639149 Free PMC article. Clinical Trial.
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Fischer K, et al. Among authors: opat s. Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21. Blood. 2017. PMID: 28325865 Free PMC article. Clinical Trial. No abstract available.
137 results